Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-09T07:45:47.136Z Has data issue: false hasContentIssue false
  • English
  • Français

Round Table Discussion: The Regulatory View on Outcome Methodologies for Pharmacologic Trials in Mild, Moderate, and Severe Alzheimer's Disease

Published online by Cambridge University Press:  07 January 2005

Ursula Kern ,
Catherine Petersen  and
Paul Leber
Get access Rights & Permissions [Opens in a new window]

Extract

Barry Reisberg: We're very fortunate in having here the regulatory persons from the United States, Canada, and Germany, in the persons of Paul Leber, Catherine Petersen, and Ursula Kern. I hope that we can proceed more or less in the fashion that the last round table went, which is your reactions as you've been listening to what you've been hearing today. And also your reactions, more generally, in terms of the field. We'll start with Dr. Kern and then Dr. Petersen and then Dr. Leber.

Type
Round Table Discussion
Information
International Psychogeriatrics , Volume 8 , Issue 2 , June 1996 , pp. 323 - 333
Copyright
© 1996 International Psychogeriatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)